Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WBRT plus Tarceva versus WBRT plus placebo in NSCLC with multiple brain metastases
ISRCTN31916843Phase 2Completed
- Sponsor
- University College London
- Start
- Jan 2008
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing WBRT + Tarceva with WBRT + placebo (2 arms). Primary endpoint: Neurological progression-free survival at 2 months. Started Jan 2008; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ISRCTN31916843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN31916843.